CB Therapeutics and Atai Life Sciences Launch TryptageniX to Sustainably Supply and Develop Clinically Relevant Compounds to Tackle the Growing Mental Health Crisis


SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) — CB Therapeutics, a biosynthesis company focused on creating ethical and environmentally-friendly products to improve mental health and increase healthspan, believes their partnership with atai Life Sciences will help to meet the growing unmet needs of patients with mental health conditions. Read More

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: